Omarigliptin (MK-3102)
![]() |
- ₹0
- Product name: Omarigliptin (MK-3102)
- CAS: 1226781-44-7
- MF: C17H20F2N4O3S
- MW: 398.43
- EINECS:682-558-0
- MDL Number:MFCD22573261
- Synonyms:(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(Methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-aMine;MK-3012;(2S,3R,5S)-2-(2,5-Difluorophenyl)-5-[2-(Methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-aMine (MK-3102 enantioMer);(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine;OMarigliptin (MK-3102);2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine MK3102;MK-3102 - M10588;MK-3102, >=98%
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Boiling point :529.4±60.0 °C(Predicted)
Density :1.61±0.1 g/cm3(Predicted)
storage temp. :2-8°C(protect from light)
solubility :insoluble in EtOH; insoluble in H2O; ≥17.15 mg/mL in DMSO
form :solid
pka :9.11±0.60(Predicted)
color :White to off-white
InChI :InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
InChIKey :MKMPWKUAHLTIBJ-ISTRZQFTSA-N
SMILES :[C@H]1(C2=CC(F)=CC=C2F)OC[C@H](N2CC3=CN(S(C)(=O)=O)N=C3C2)C[C@@H]1N
CAS DataBase Reference :1226781-44-7
Density :1.61±0.1 g/cm3(Predicted)
storage temp. :2-8°C(protect from light)
solubility :insoluble in EtOH; insoluble in H2O; ≥17.15 mg/mL in DMSO
form :solid
pka :9.11±0.60(Predicted)
color :White to off-white
InChI :InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
InChIKey :MKMPWKUAHLTIBJ-ISTRZQFTSA-N
SMILES :[C@H]1(C2=CC(F)=CC=C2F)OC[C@H](N2CC3=CN(S(C)(=O)=O)N=C3C2)C[C@@H]1N
CAS DataBase Reference :1226781-44-7
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Merck earned its first global approval for omarigliptin in Japan in 2015, and phase III development is ongoing in other countries around the globe for this interesting small molecule DPP-4 inhibitor. Interestingly, while most DPP-4 inhibitors used to treat type 2 DM require daily administration, omarigliptin is a weekly treatment. The process-scale synthesis of omarigliptin has been nicely described in an October 2015 paper from the Merck process group.Related product price
- 221176-49-4
₹56971.98